Cited by 2,472Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and ApplicationsStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Open access

Seymour, Lesley, Bogaerts, Jan, Perrone, Andrea, Ford, Robert, Schwartz, Lawrence H, Mandrekar, Sumithra, Lin, Nancy U, Litière, Saskia, Dancey, Janet, Chen, Alice, Hodi, F Stephen, Therasse, Patrick, Hoekstra, Otto S, Shankar, Lalitha K, Wolchok, Jedd D, Ballinger, Marcus, Caramella, Caroline, de Vries, Elisabeth G E·2017·The Lancet Oncology

DOI 10.1016/s1470-2045(17)30074-8PMC PMC5648544

Open this paper in CoChat — free account

Abstract

Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30074-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citation
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citation
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Show all 37 references

Sorted by citations

Items 101–200 of 1,001

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
Lu, J., Zhang, P., Huang, X., Guo, X.-J., Gao, C., Zeng, H., Zheng, Y.-M., Wang, S., Cai, J., Sun, Q., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01207-x · Cited by 168
Immunotherapy in Breast Cancer
Dvir, K., Giordano, S. B., & Leone, J. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147517 · Cited by 184
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
Mushti, S. L., Mulkey, F. A., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 166
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Serratì, S., Guida, M., Fonte, R., Summa, S. D., Strippoli, S., Iacobazzi, R. M., Quarta, A., Risi, I. D., Guida, G., Paradiso, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01490-9 · Cited by 170
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Habra, M. A., Stephen, B., Campbell, M. T., Hess, K. R., Tapia, C., Xu, M., Rodon, J. A., Jiménez, C., Lee, J. E., Perrier, N. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0722-x · Cited by 160
Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management
Kalisz, K. R., Ramaiya, N. H., Laukamp, K. R., & Gupta, A. B. (2019) · Radiographics · doi:10.1148/rg.2019190036 · Cited by 158
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
Gandara, D. R., von Pawel, J., Mazières, J., Sullivan, R., Helland, Å., Han, J., Ponce-Aix, S., Rittmeyer, A., Barlési, F., Kubo, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2027 · Cited by 155
Self-citation
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
Tsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 155
Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images
Tian, P., He, B., Mu, W., Liu, K., Liu, L., Zeng, H., Liu, Y.-J., Jiang, L.-L., Zhou, P., Huang, Z., et al. (2021) · Theranostics · doi:10.7150/thno.48027 · Cited by 151
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
Wei, C., Zhu, M.-X., Zhang, P., Huang, X., Wan, J., Yao, X., Hu, Z.-T., Chai, X., Peng, R., Yang, X., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.019 · Cited by 158
How rapid advances in imaging are defining the future of precision radiation oncology
Beaton, L., Bandula, S., Gaze, M. N., & Sharma, R. A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0412-y · Cited by 152
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.
Ma, Y., Wang, Q., Dong, Q., Zhan, L., & Zhang, J. (2019) · PubMed Central · Cited by 151
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Zhang, L., Mai, W., Jiang, W., & Geng, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594558 · Cited by 157
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Lim, S. Y., Shklovskaya, E., Lee, J., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R. P. M., Menzies, A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36979-y · Cited by 161
Meeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 155
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Xie, L., Xu, J., Sun, X., Guo, W., Gu, J., Liu, K., Zheng, B., Ren, T., Huang, Y., Tang, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000798 · Cited by 145
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144
Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression
Galldiks, N., Köcher, M., Ceccon, G. S., Werner, J., Brunn, A., Deckert, M., Pope, W. B., Soffietti, R., Rhun, É. L., Weller, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz147 · Cited by 143
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Ko, C., Yeh, L., Kuo, Y., & Chen, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00306-8 · Cited by 145
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Pernas, S., Martín, M., Kaufman, P. A., Gil-Martín, M., Pardo, P. G., López‐Tarruella, S., Manso, L., Ciruelos, E. M., Fidalgo, J. A. P., Hernándo, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30147-5 · Cited by 143
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Colombo, N., Biagioli, E. C., Harano, K., Galli, F., Hudson, E. R., Antill, Y. C., Choi, C. H., Rabaglio, M., Marmé, F., Marth, C., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00334-6 · Cited by 149
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001945 · Cited by 142
Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Gauci, M.-L., Lanoy, É., Champiat, S., Caramella, C., Ammari, S., Aspeslagh, S., Varga, A., Baldini, C., Bahleda, R., Gazzah, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0793 · Cited by 142
Self-citation
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
Cheng, Y., Chen, J., Zhang, W., Xie, C., Hu, Q., Zhou, N., Huang, C., Wei, S., Sun, H., Li, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03132-1 · Cited by 144
“Secondary endpoints were as follows: PFS assessed by the investigator per RECIST 1.1 and iRECIST 29 ; the IRC-assessed objective response rate as per RECIST 1.1 (defined as the percentage of participants achieving complete response and partial response); disease control rate (defined as the…”
Influential
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
Armato, S. G., & Nowak, A. K. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.034 · Cited by 140
Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 145
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities
Kanjanapan, Y., Day, D., Wang, L. E., Al‐Sawaihey, H., Abbas, E., Namini, A., Siu, L. L., Hansen, A. R., Razak, A. A., Spreafico, A., et al. (2019) · Cancer · doi:10.1002/cncr.31999 · Cited by 141
Phase I trials as valid therapeutic options for patients with cancer
Adashek, J. J., LoRusso, P. M., Hong, D. S., & Kurzrock, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0262-9 · Cited by 141
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, É., Massard, C., Robert, C., Ammari, S., de Baère, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0473 · Cited by 141
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 143
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Antill, Y. C., Kok, P., Robledo, K. P., Yip, S., Cummins, M. M., Smith, D. S., Spurdle, A. B., Barnes, E. H., Lee, Y. C., Friedlander, M. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002255 · Cited by 140
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Adams, S., Othus, M., Patel, S. P., Miller, K. D., Chugh, R. K., Schuetze, S. M., Chamberlin, M. D., Haley, B. J., Storniolo, A. M., Reddy, M. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2182 · Cited by 136
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
Ju, W., Xia, R., Zhu, D., Dou, S., Zhu, G., Dong, M., Wang, L., Sun, Q., Zhao, T., Zhou, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33080-8 · Cited by 143
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 145
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, M., Scheiner, B., & Pinato, D. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00147-4 · Cited by 139
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
Structural and functional radiomics for lung cancer
Wu, G., Jochems, A., Refaee, T., Ibrahim, A., Yan, C., Sanduleanu, S., Woodruff, H. C., & Lambin, P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05242-1 · Cited by 141
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 137
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
Seban, R., Nemer, J. S., Marabelle, A., Yeh, R., Deutsch, É., Ammari, S., Moya‐Plana, A., Mokrane, F., Gartrell, R. D., Finkel, G. G., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04411-7 · Cited by 136
Self-citation
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 134
“Age, years Median (range) 63 (21-85) 65 and older 45 (43.”
Background
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Mettu, N. B., Ou, F., Zemla, T., Halfdanarson, T. R., Lenz, H., Breakstone, R., Boland, P. M., Crysler, O., Wu, C. S.-Y., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 135
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Hyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 130
The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
Gerwing, M., Herrmann, K., Helfen, A., Schliemann, C., Berdel, W. E., Eisenblätter, M., & Wildgruber, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0169-5 · Cited by 130
Review of cancer treatment with immune checkpoint inhibitors
Thallinger, C., Füreder, T., Preusser, M., Heller, G., Müllauer, L., Höeller, C., Prosch, H., Frank, N., Świerzewski, R., Berger, W., et al. (2017) · Wiener klinische Wochenschrift · doi:10.1007/s00508-017-1285-9 · Cited by 134
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Muik, A., Garralda, E., Altıntaş, I., Gieseke, F., Geva, R., Ben‐Ami, E., Maurice‐Dror, C., Calvo, E., LoRusso, P. M., Alonso, G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1345 · Cited by 130
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 131
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 143
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 123
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Gouda, M. A., Jankú, F., Wahida, A., Buschhorn, L., Schneeweiß, A., Karim, N. A., de Miguel‐Pérez, D., Re, M. D., Russo, A., Curigliano, G., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.007 · Cited by 120
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers
Ritchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
Ghini, V., Laera, L., Fantechi, B., Monte, F. D., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020) · Cancers · doi:10.3390/cancers12123574 · Cited by 124
A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
Wang, S., Liu, Y., Feng, Y., Zhang, J., Swinnen, J. V., Li, Y., & Ni, Y. (2019) · Cancers · doi:10.3390/cancers11111782 · Cited by 123
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
Queirolo, P., Boutros, A., Tanda, E. T., Spagnolo, F., & Quaglino, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.001 · Cited by 120
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 124
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
Mekki, A., Dercle, L., Lichtenstein, P., Marabelle, A., Michot, J., Lambotte, O., Pavec, J. L., Martin, E. D., Balleyguier, C., Champiat, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.006 · Cited by 118
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0020 · Cited by 119
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
de Miguel‐Pérez, D., Russo, A., Arrieta, O. G., Ak, M., Barrón, F., Gunasekaran, M., Mamindla, P., Lara‐Mejía, L., Peterson, C. B., Er, M. E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02379-1 · Cited by 121
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
You, B., Bolze, P., Lotz, J., Massardier, J., Gladieff, L., Joly, F., Hajri, T., Maucort‐Boulch, D., Bin, S., Rousset, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00803 · Cited by 119
Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
Zhang, L., Zheng, H., Jiang, S., Liu, Y.-G., Zhang, T., Zhang, J., Lü, X., Zhao, H., Sang, X., & Xu, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001022 · Cited by 120
“One evaluated the incidence and mortality of various cancer worldwide [35] and one established guideline for immunotherapy responses [53] .”
Background
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy
Fakih, M., Sandhu, J. S., Lim, D. W., Li, X., Li, S., & Wang, C. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7845 · Cited by 122
Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Katz, S. I., Hammer, M. M., Bagley, S. J., Aggarwal, C., Bauml, J. M., Thompson, J. C., Nachiappan, A. C., Simone, C. B., & Langer, C. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.010 · Cited by 112
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Pignon, J., Jegede, O. A., Shukla, S. A., Braun, D. A., Horak, C. E., Wind‐Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3206 · Cited by 117
Self-citation
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 119
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 123
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
Westdorp, H., Creemers, J. H. A., van Oort, I. M., Schreibelt, G., Gorris, M. A. J., Mehra, N., Simons, M., de Goede, A. L., van Rossum, M. M., Croockewit, A. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0787-6 · Cited by 114
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
Mazzaschi, G., Minari, R., Zecca, A., Cavazzoni, A., Ferri, V., Mori, C., Squadrilli, A., Bordi, P., Buti, S., Bersanelli, M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.028 · Cited by 117
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Chu, Q. S.-C., Perrone, F., Greillier, L., Tu, W., Piccirillo, M. C., Grosso, F., Russo, G. L., Florescu, M., Mencoboni, M., Morabito, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01613-6 · Cited by 116
Self-citation
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
Camidge, D. R., Lee, E. Q., Lin, N., Margolin, K. A., Ahluwalia, M. S., Bendszus, M., Chang, S. M., Dancey, J. E., de Vries, E. G. E., Harris, G. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30693-9 · Cited by 109
Self-citation
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Karaboué, A., Collon, T., Pavese, I., Bodiguel, V., Cucherousset, J., Zakine, E., Innominato, P. F., Bouchahda, M., Adam, R. A., & Lévi, F. (2022) · Cancers · doi:10.3390/cancers14040896 · Cited by 111
A CT-based Radiomics Signature is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology · doi:10.1148/radiol.2021200928 · Cited by 107
Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics
Podlesny, D., Durdevic, M., Paramsothy, S., Kaakoush, N. O., Högenauer, C., Gorkiewicz, G., Walter, J., & Fricke, W. F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100711 · Cited by 111
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Manson, G., Maria, A. T. J., Poizeau, F., Danlos, F., Kostine, M., Brosseau, S., Aspeslagh, S., du Rusquec, P., Roger, M., Pallix-Guyot, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0821-8 · Cited by 108
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer
Cascone, T., Weissferdt, A., Godoy, M. C. B., William, W. N., Leung, C. H., Lin, H. Y., Basu, S., Yadav, S. S., Pataer, A., Mitchell, K. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25188-0 · Cited by 107
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017) · Radiographics · doi:10.1148/rg.2017170085 · Cited by 107
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
Sachpekidis, C., Anwar, H., Winkler, J. K., Kopp‐Schneider, A., Larribère, L., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3972-9 · Cited by 106
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
Kim, J. Y., Lee, K. H., Kang, J., Borcoman, É., Saâda-Bouzid, E., Kronbichler, A., Hong, S. H., Rezende, L. F. M., Ogino, S., Keum, N., et al. (2019) · Cancers · doi:10.3390/cancers11111699 · Cited by 104
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 109
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Xu, W., Liu, K., Chen, M., Sun, J., McCaughan, G. W., Lu, X., & Ji, J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919862692 · Cited by 103
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Katz, S. C., Hardaway, J. C., Prince, E. A., Guha, P., Cunetta, M., Moody, A. E., Wang, L., Armenio, V. A., Espat, N. J., & Junghans, R. P. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0104-z · Cited by 106
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 105
Self-citation
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., & Mittra, E. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002453 · Cited by 101
Hyperprogression as a distinct outcome after immunotherapy
Fuentes‐Antrás, J., Provencio, M., & Díaz‐Rubio, E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.006 · Cited by 103
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub3 · Cited by 101
Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Russo, A., Franchina, T., Ricciardi, G. R. R., Battaglia, A., Scimone, A., Berenato, R., Giordano, A., & Adamo, V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26609 · Cited by 100
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
Fan, Y., Li, S., Ding, X., Yue, J., Jiang, J., Zhao, H., Hao, R., Qiu, W., Liu, K., Li, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5471-1 · Cited by 100
Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy
Levi, J., Lam, T., Goth, S. R., Yaghoubi, S. S., Bates, J., Ren, G., Jivan, S., Huynh, T. L., Blecha, J. E., Khattri, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0267 · Cited by 100
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
Haddad, R. I., Concha‐Benavente, F., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., Kasper, S., Vokes, E. E., Worden, F. P., et al. (2019) · Cancer · doi:10.1002/cncr.32190 · Cited by 99
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Patel, R. R., He, K., Barsoumian, H. B., Chang, J. Y., Tang, C. Z., Verma, V., Comeaux, N. I., Chun, S. G., Gandhi, S. J., Truong, M. T., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.037 · Cited by 105
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
Kok, I. C., Hooiveld-Noeken, J. S., van de Donk, P. P., Giesen, D., van der Veen, E. L., Hooge, M. N. L., Brouwers, A. H., Hiltermann, T. J. N., van der Wekken, A. J., Hijmering-Kappelle, L. B. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.10.213 · Cited by 99
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
Carretero-González, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepúlveda-Sánchez, J. M., Lopez-Martin, J. A., Paz-Ares, L. G., & de Velasco, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24283 · Cited by 103
Imaging of tumour response to immunotherapy
Dromain, C., Beigelman‐Aubry, C., Pozzessere, C., Durán, R., & Digklia, A. (2020) · European Radiology Experimental · doi:10.1186/s41747-019-0134-1 · Cited by 99
Imaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 99
Objective response rate assessment in oncology: Current situation and future expectations
Aykan, N. F., & Özatlı, T. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i2.53 · Cited by 97
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Frélaut, M., du Rusquec, P., Moura, A. D., Tourneau, C. L., & Borcoman, É. (2020) · BioDrugs · doi:10.1007/s40259-020-00425-y · Cited by 104
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
Ahn, S., & Kim, K. (2021) · Modern Pathology · doi:10.1038/s41379-021-00823-9 · Cited by 97
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Tan, D. S. W., Felip, E., de Castro, G., Solomon, B., Greystoke, A., Cho, B. C., Cobo, M., Kim, T. M., Ganguly, S., Carcereny, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00980 · Cited by 97

Authors: Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., Hodi, F. S., Therasse, P., Hoekstra, O. S., Shankar, L. K., Wolchok, J. D., Ballinger, M., Caramella, C., & de Vries, E. G. E.
Affiliations: Queen's University (CA)
European Organisation for Research and Treatment of Cancer (BE)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
NewYork–Presbyterian Hospital (US)
Mayo Clinic (US)
National Institutes of Health (US)
Harvard University (US)
Institut de Recherches Internationales Servier (France) (FR)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Memorial Sloan Kettering Cancer Center (US)
Genentech (US)
Institut Gustave Roussy (FR)
Corresponding author: Seymour, Lesley
ORCID: Seymour, Lesley
Bogaerts, Jan
Ford, Robert
Mandrekar, Sumithra
Litière, Saskia
Dancey, Janet
Chen, Alice
Hodi, F Stephen
Hoekstra, Otto S
Shankar, Lalitha K
Wolchok, Jedd D
Caramella, Caroline
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2017-03
Volume: 18
Issue: 3
Pages: e143-e152
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(17)30074-8
PMC: PMC5648544
OpenAlex: W2592144107
Cited by: 2,472
References: 37
Citations by year: 2026: 264 · 2025: 267 · 2024: 319 · 2023: 305 · 2022: 270 · 2021: 308 · 2020: 304 · 2019: 223 · 2018: 146 · 2017: 62
FWCI: 21.17
Type: journal article
Language: en
Update notices: erratum (2019-05-01)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Pure Amsterdam UMC (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (U10CA011488, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: iRECIST, cancer immunotherapy, response evaluation criteria, disease progression, immunomodulators, clinical trial data collection, data warehouse
MeSH terms: Humans, Immunotherapy, Neoplasms, Practice Guidelines as Topic, Disease Progression, Tumor Burden, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks